Biotech / Finance

<b>Trump</b> NIH Cuts Would Be 'Catastrophic Event,' Says Bush-Era <b>NIH</b> Chief

Mar 16 8:00pm BioSpace.com Featured News and Stories
  Life Sciences Jobs   ...
Read More

3 Numbers That Make Gilead Look Cheaper Than It Really Is

Mar 16 8:00pm BioSpace.com Featured News and Stories
  Life Sciences Jobs   ...
Read More

What Makes Cara Therapeutics So Intriguing?

Mar 16 8:00pm BioSpace.com Featured News
  Life Sciences Jobs   ...
Read More

Why This Biotech Says It's Close to Curing the Type of Cancer That Killed

Mar 16 8:00pm BioSpace.com Featured News
  Life Sciences Jobs   ...
Read More

Valeant shares pop 4% after activist investor ValueAct ups stake

Mar 16 5:59pm Health Care
The hedge fund reported that it bought 3 million more shares on Tuesday, increasing its stake to about 5.2 percent.
Read More

White House Budget Chief: Trump 'absolutely going to keep' promises on Social Security, Medicare

Mar 16 5:30pm Health Care
Trump said on the campaign trail that he would not cut Social Security or Medicare.
Read More

Arbutus Licenses LNP Delivery Technology to Alexion for Use in Single Messenger RNA Product Candidate

Mar 16 5:00pm Biotech
VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 16, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus (HBV) infection, today announced it has licensed to Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) its proprietary lipid nanoparticle (LNP) technology for exclusive use in one of Alexion's rare disease programs. This transaction enables Alexion to address delivery for therapeutic application of messenger RNA (mRNA) and rapidly enter clinical development with its mRNA product candidate.  Under the terms of the license agreement, Alexion will pay Arbutus $7.5 million upfront, and payments of up to $75 million for achievement of development, regulatory, and commercial milestones, as well as single digit royalties. In addition, Arbutus will conduct technology development and provide manufacturing and regulatory support for the rapid advancement of Alexion's mRNA product candidate. "This agreement validates our leadership position in LNP technology and underscores the value of this platform in enabling RNA therapeutics. We are excited to be working with Alexion to advance a treatment for rare disease," said Dr. Mark J. Murray, Arbutus' President and CEO. "Our core focus as a company remains the cure ...Full story available on Benzinga.com...
Read More

Cannabinoid-based chewing gum enrolls patients in Ph II trial

Mar 16 4:11pm in-PharmaTechnologist RSS
Axim Biotech has enrolled patients in its Phase II trial for Canchew Plus chewing gum – a delivery method with a “cumulative effect,” says CEO.
Read More

Trump NIH Cuts Would Be Catastrophic Event, Says Bush-Era NIH Chief

Mar 16 3:31pm The Medicine Show
It will be a catastrophic event because the NIH funds grants over four or five years and therefore only has 20\% of its budget to give at any one year, former NIH head Elias Zerhouni says. I find it disturbing, to be honest with you. ...
Read More

No evidence Trump Tower was wiretapped, Senate intelligence committee leaders say

Mar 16 2:06pm Health Care
The Senate Intelligence Committee sees no evidence supporting President Trump's claim he was wiretapped.
Read More

Trump says 'I know' Clinton voters would do better than his voters under GOP's health plan

Mar 16 1:57pm Health Care
Counties voting for Trump would see a tax-cut windfall three times less than the windfall for Clinton-leaning counties.
Read More

Sneak Peek into My Upcoming Pregnancy Guide!

Mar 16 12:30pm Pregnancy – Mama Natural
Have you ever worked on something so hard and for so long that, when you finally look back on it, you’re a little shocked by how far you’ve come? I guess it’s a little like parenting. You pour in countless long nights and patient moments and an enormity of love and compassion, and then suddenly […] The post Sneak Peek into My Upcoming Pregnancy Guide! appeared first on Mama Natural.
Read More

Strip mall stem cells

Mar 16 11:59am Health News Review
If you had been in Salt Lake City last month, savoring your morning coffee, and watching this channel 4 morning show, you might have been treated to this video promising a “revolutionary” treatment that assures “you don’t have to live with back pain.” You’d also be assured that the doctor being interviewed, Dr. Kahn, works at the only […]...
Read More

House budget panel backs Republican health care plan

Mar 16 10:57am Health Care
The vote moves the legislation to a final committee before sending it for a vote before the full House.
Read More

WEATHER CHANGES SO SHOULD YOU

Mar 16 10:21am Destination Maternity Blog
Depending on where you live, you may be soaking up the sun or shoveling the snow. The start of spring is fickle, which is why transitional maternity styles are the most essential. No matter what the skies are doing in your area, you can still be a FASHION-FORWARD force of nature! The classic leggings and […]...
Read More

Biogen shares drop after Morgan Stanley downgrade; rest of biotech also dragged lower

Mar 16 10:06am Health Care
Biogen shares are fully valued following the spinoff of its hemophilia business, Morgan Stanley argues.
Read More

The Martin Shkreli musical is bound for Off-Broadway, just as the 'pharma bro' heads to trial

Mar 16 10:05am Health Care
The musical features a number of absurd things about the notorious provocateur Shkreli, many of which happen to be true.
Read More

Climate change is making us sick, top U.S. doctors say

Mar 16 9:50am Health Care
The types of harm can range from injuries and death to depression and anxiety, USA Today reports.
Read More

Helmsley Charitable Trust and Akston Biosciences Corporation Announce Partnership to Advance Novel Technology to Treat Type 1 Diabetes

Mar 16 9:33am Biotech
NEW YORK, NY and BEVERLY, MA, March 16, 2017 (GLOBE NEWSWIRE) -- The Leona M. and Harry B. Helmsley Charitable Trust and Akston Biosciences Corporation today announced a partnership to advance Akston's novel insulin engineering technology to prevent the clinical onset of type 1 diabetes. Akston's lead product candidate, AKS-107, is designed to be injected in at-risk, pre-diabetic individuals to disrupt problematic cells that may be responsible for type 1 diabetes, thereby reducing the chances that individuals develop diabetes. As part of the agreement, Helmsley will provide up to $3.1 million over the next two years to support manufacturing development, preclinical safety and efficacy testing, and regulatory filings to advance AKS-107 into clinical trials. The partnership is structured as a program-related investment (PRI) in the form of a loan to Akston. "At Helmsley, we are always seeking to expand the set of tools that we can use to advance our mission while supporting the goals we share with our partners. The PRI is a powerful way to catalyze meaningful change," said Gina Agiostratidou, Ph.D., MBA, Director of Helmsley's Type 1 Diabetes Program. "We see tremendous value in working with creative companies like Akston who aim to develop innovative therapies to help people struggling daily with a relentless disease." In type 1 diabetes, the body mistakenly recognizes its own insulin-producing cells as foreign and ...Full story available on Benzinga.com...
Read More

Egalet Says FDA Saw Unintended Consequence Of IV Abuse Potential With Endo's Opana ER

Mar 16 9:07am FDA
The U.S. Food and Drug Administration reached a conclusion this week concerning Endo International plc - Ordinary Shares (NASDAQ: ENDP)'s therapy Opana ER, which is intended to treat pain severe enough to require a daily, around-the-clock, long-term opioid treatment. An independent FDA panel found the benefits of Endo's therapy no longer outweighs the risks of abuse. Opioid abuse, overdose and addiction is a major concern across the U.S. and this prompted a panel to address Endo's Opana ER, which was first approved in 2006 and a new formulation was introduced in 2012 to deter abuse. Effect On Egalet Egalet Corp (NASDAQ: EGLT), a specialty pharmaceutical company that develops and ...Full story available on Benzinga.com...
Read More

US FDA says Badrivishal can't ensure safety of river water used at API plant

Mar 16 9:00am in-PharmaTechnologist RSS
The US FDA has criticised Badrivishal Chemicals & Pharmaceuticals for failing to document production and monitor the efficacy of water purification systems at its API plant in Maharashtra.  ...
Read More

What's In Store For AVXS Today?

Mar 16 5:18am RTT - Biotech
Shares of AveXis Inc. (AVXS) have gained more than 50\% year-to-date and trade around $74.00.
Read More

From skin to brain: Stem cells without genetic modification

Mar 16 5:00am Nanowerk Biotech News
New study yields neural crest cells from adult skin cells, and could lead to new treatments for Parkinson's and other brain illnesses.            ...
Read More

Scientists link noncoding genetic variants to neurodevelopmental disorders

Mar 16 5:00am PBR - News
Scientists from the Max Planck Institute for Psycholinguistics and Radboud University in Nijmegen found that genetic variation in the non-coding DNA may lead to language impairments in children and other neurodevelopmental disorders such as schizophrenia, autism, and bipolar disorder.
Read More

When proteins court each other, the dance moves matter

Mar 16 4:52am Nanowerk Biotech News
On the biological dance floor, careful choreography may decide how well a suitor is able to woo a partner.            ...
Read More

UK's MHRA grants early access to Sanofis dermatology treatment

Mar 16 4:45am PBR - News
The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Sanofi’s dupilumab, an investigational treatment for atopic dermatitis (AD), a positive scientific opinion through the Early Access to Medicines Scheme (EAMS).
Read More

Catalyst Pharmaceuticals neuromuscular drug succeeds in seven-patient trial

Mar 16 4:08am PBR - News
Catalyst Pharmaceuticals said its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a debilitating neuromuscular disease, met the main goals of a study.
Read More

After Soaring to $150, Can Incyte Stir Up More Upside?

Mar 15 8:00pm BioSpace.com Featured News and Stories
  Life Sciences Jobs   ...
Read More

300 Employees Impacted as Teva to Shut Down or Sell Philadelphia Plant

Mar 15 8:00pm BioSpace.com Featured News
  Life Sciences Jobs   ...
Read More

Tips for expecting a multiple birth

Mar 15 7:00pm pregnancy – Hubbub
Are you expecting twins? Or more? The discovery of being pregnant with multiples can be quite a shock, even if you knew your chances of twins (or more) was higher than normal – if it “runs in the family”, for example, or you had an assisted conception. Often accompanying the shock is the anxiety and a multitude of questions… will I make it to full term? can I have a vaginal birth? how am I going to look after two (or more) babies at once? how are we going to afford this? will I be able to go back to work? do I need to buy two or more of everything? how is this going to affect my existing children? do we have to buy another car and move house? When expecting multiples so many things change, your due date changes – if you are having twins usually 38 weeks is considered full term, 36 weeks for triplets and 34 weeks for quads. Mothers have extra check-ups, extra scans and particularly,… Read the rest...
Read More

Brain aging linked to common genetic variant

Mar 15 2:48pm Health Care
Researchers found a genetic variant that seems to have a big impact on how quickly brains age in older people.
Read More

Accelerate Diagnostics Names Tom Brown to Board of Directors

Mar 15 12:15pm Biotech
TUCSON, Ariz., March 15, 2017 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. today announced the election of Tom Brown to the company's board of directors. His appointment is effective March 14, 2017. Brown's appointment adds over 30 years of medical diagnostics expertise to the company's board of directors. Beginning his career with the Abbott Laboratories Diagnostics Division (ADD) in 1974, Brown held numerous sales, marketing and general management positions of increasing responsibility. He served in positions including Divisional Vice President of Sales within the United States, and Divisional Vice President and General Manager of the Western Hemisphere, and by 1993 he was Corporate Vice President of Worldwide Diagnostic Commercial Operations. He was named Senior Vice President before becoming President of the Diagnostic Division, the role he served until his retirement in 2002. Tom is a proven leader with a wealth of experience in the diagnostics industry, said Chairman of the Board, John Patience. His extensive background, particularly in launching and commercializing ...Full story available on Benzinga.com...
Read More

Misbranded epilepsy drug API lands FDA warning for Chinese ingredient maker

Mar 15 11:45am in-PharmaTechnologist RSS
The US FDA has slammed China’s Lumis Global Pharmaceuticals for problems documenting and labelling active pharmaceutical ingredients.
Read More

Breast cancer and the ballot box: political messages about screening prioritize votes over informed decisions

Mar 15 11:17am Health News Review
In late February, the New York Department of Financial Services trumpeted this news to reporters: “Governor Cuomo Announces Action To Expand Cutting-Edge Breast Cancer Screening Options For Women.” The news release noted that New York’s health insurers must cover medically necessary 3-D mammograms without co-pays, coinsurance, and deductibles. The governor called his action “the most […]...
Read More

Health insurers start getting the hang of Obamacare as GOP pushes replacement plan

Mar 15 10:58am Health Care
Results from this large Obamacare health provider suggest the tide is beginning to turn for insurers.
Read More

It's your plan, Mr. Trump Speaker Ryan says president co-wrote embattled Obamacare replacement

Mar 15 10:18am Health Care
The bill is drawing fire from conservatives, who say it doesn't go far enough to repeal Obamacare.
Read More

Trump's media allies urge him to dump House Obamacare repeal plan

Mar 15 10:02am Health Care
Some staunch Trump supporters in the media sense a political calamity for the president, who promised insurance for all.
Read More

What's The Catalyst Driving CPRX?

Mar 15 10:00am RTT - Biotech
Catalyst Pharmaceuticals Inc. (CPRX) has reported encouraging results from an investigator-sponsored trial evaluating its investigational drug candidate Firdapse as a treatment for myasthenia gravis patients with anti-MuSK antibodies.
Read More

The pollution of health news: Time to drain the swamp

Mar 15 9:26am Health News Review
The BMJ asked me to comment on so-called fake health news.  The journal published my editorial today. With the journal’s permission, here is the full text.  (The pollution image did not appear in The BMJ.) Pollution of health news: Time to drain the swamp US President Donald Trump placed the term fake news in the global lexicon […]...
Read More

Lynparza Vs. Niraparib

Mar 15 8:32am Biotech
Shares of TESARO Inc (NASDAQ: TSRO) fell more than 10 percent Tuesday after AstraZeneca plc (ADR) (NYSE: AZN) presented better trial results for its ovarian cancer drug. In a related development, shares of Clovis Oncology Inc (NASDAQ: CLVS) gained more than 10 percent to set a new 52-week high of $68.58. Clovis’s PARP inhibitor Rucaparib is being studied for ovarian cancer. The PARP inhibitors of Tesaro’s Niraparib and Astrazeneca’s Lynparza are fighting to gain market share in the oncology space. However, the positive data from Lynparza could hamper the commercial prospects of Niraparib and should support an approval in earlier lines of treatment for Lynparza. Lynparza In a late stage study, AstraZeneca’s Lynparza showed a significant improvement in progression-free survival (PFS) in germline ...Full story available on Benzinga.com...
Read More

Cell Design Labs Announces Issuance of Broad Patent for Programmable Car-T Cells to Treat Cancer and Other Diseases

Mar 15 8:00am Biotech
SAN FRANCISCO, March 15, 2017 (GLOBE NEWSWIRE) -- Cell Design Labs, Inc. today announced the issuance of U.S. Patent No. 9,587,020, entitled, Chimeric Antigen Receptor and Methods of Use Thereof. This patent, issued to UC San Francisco (UCSF) and exclusively licensed to Cell Design Labs, broadly covers composition of matter and methods of use for the company's proprietary THROTTLE Switch™ technology in chimeric antigen receptor T cells (CAR-T cells). This overarching patent provides comprehensive coverage for our proprietary switch, a method of engineering a dynamic CAR-T cell for increased safety and control by incorporating activation by an ‘off-the-shelf' FDA-approved molecule, said Brian Atwood, Co-Founder, President and Chief Executive Officer of Cell Design Labs. Currently, we are working with Kite Pharma to add our THROTTLE Switch technology to their therapeutic CAR-T cells designed to treat acute myeloid leukemia, and we ...Full story available on Benzinga.com...
Read More

Getting Into The Business Of Medical Marijuana: An Interview With IGC CEO Ram Mukunda

Mar 15 7:47am Biotech
Engineering graduate Ram Mukunda spent more than 25 years working in Wall Street. He served in companies communications firms Intelsat SA (NYSE: I) and Startec, before making an incursion into the mining industry through a company he co-founded. India Globalization Capital, Inc. (NYSE: IGC) was focused on the beneficiation of iron ore, which means it took low-grade iron ore and converted it to high-grade. However, a few years ago, iron ore prices plummeted from $180 per dry metric ton to roughly $40, in many cases selling below its cost of production. It was then Mukunda had to make a tough call. “[We wanted] something that was more U.S.-centric, and we really liked the cannabis industry. We have now been working on it for over three years,” Mukunda told Benzinga. Getting Into Cannabis Benzinga: How does a telecom and mining-savvy mathematician and engineer decide to get in the marijuana business? Mukunda: About three years ago (…) we started looking at the [cannabis] industry and trying to figure out how to position ourselves. So what we did is we came up with this approach: The industry is probably made up of three concentric circles. The first one are people who actually touch the plant; these are the growers and the processors [such as CANOPY GROWTH CORP COM NPV (OTC: TWMJF) and AURORA CANNABIS IN COM NPV (OTC: ACBFF)]. Then you have the second group, which are people who supply things to the guys who touch the plant, the LED makers and so on. Then you have the third circle, which really is more of the people who are directly or indirectly part of the industry, say for ...Full story available on Benzinga.com...
Read More

DSM Sinochem licenses enzymatic antibiotic production tech to Sandoz; sues Weiqida

Mar 15 7:00am in-PharmaTechnologist RSS
DSM Sinochem Pharmaceuticals has licensed enzyme-based antibiotic production IP to Sandoz and accused Sinopharm Weiqida Pharmaceutical of patent infringement.
Read More

AstraZeneca's Lynparza shows significant survival benefit in ovarian cancer study

Mar 15 6:35am PBR - News
A phase 3 clinical trial evaluating AstraZeneca's PARP inhibitor Lynparza (olaparib) as maintenance therapy in ovarian cancer demonstrated a pronounced extension in survival compared to placebo.
Read More

CRISPR Therapeutics licenses cell engineering platform from MaxCyte

Mar 15 6:30am PBR - News
CRISPR Therapeutics and Casebia Therapeutics, its joint venture with Bayer, have signed a licensing agreement for a cell transfection platform from MaxCyte.
Read More

Pfizer launches Zavicefta in UK and Germany

Mar 15 6:01am PBR - News
Pfizer has launched Zavicefta (ceftazidime/avibactam), a combination antibiotic to treat Gram-negative bacterial infections requiring hospitalization, in the UK and Germany.
Read More

Protein dosage compensation mechanism unravelled

Mar 15 4:17am Nanowerk Biotech News
Scientists have discovered which genes from the yeast genome exhibit dosage compensation - the ability to temper protein production when the corresponding encoding gene?s copy number increases. In addition, they identify the underlying process to be protein degradation, and link the mechanism to stoichiometric buffering of protein complex subunits.            ...
Read More

Many Americans were skeptical of GOP's Obamacare replacement even before CBO predicted losses

Mar 15 3:00am Health Care
Almost half of the public thinks fewer people would be insured and that health costs would be higher under the GOP plan.
Read More

FDA approves Merck's Keytruda for Hodgkin lymphoma

Mar 15 2:23am PBR - News
Merck has secured another approval from from the US Food and Drug Administration (FDA) for Keytruda, this time for classical Hodgkin lymphoma.
Read More

FDA Panel Snubs ENDP, Watch Out For TCON, MRK's Keytruda Scores Another Win

Mar 15 2:15am RTT - Biotech
An FDA panel, which reviewed Endo International plc's (ENDP) new formulation of Opana ER designed to be crush-resistant, has voted 18 to eight, with one abstention, that the benefits of the drug no longer outweigh its risks.
Read More

Week 25: Waiting and wondering

Mar 15 12:00am Knocked Up – Pregnancy & Newborn Magazine
At this point in my pregnancy, I’m still popping by my OB’s office every four weeks to make sure Birdie and I are A-OK. Most of the time I try to avoid doctor visits, but from the moment my appointment ends, … Continue reading → The post Week 25: Waiting and wondering appeared first on Pregnancy & Newborn Magazine.
Read More

Gainers & Losers Of Mar.14: CVRS, OCX, OFIX, PETX, AMPH...

Mar 14 11:03pm RTT - Biotech
The following are some of the biotech stocks that made their way onto the Day's Gainers & Losers' list of March 14, 2017.
Read More

Here's Why Aratana Therapeutics Is Getting Clobbered

Mar 14 8:00pm BioSpace.com Featured News and Stories
  Life Sciences Jobs   ...
Read More

How This Drug Giant Plans To Cure Disease...Without Drugs

Mar 14 8:00pm BioSpace.com Featured News and Stories
  Life Sciences Jobs   ...
Read More

3 Reasons Why Gilead Will Buy Incyte&mdash;and 1 Reason Why It Won't

Mar 14 8:00pm BioSpace.com Featured News and Stories
  Life Sciences Jobs   ...
Read More

Roche Diabetes Care to Chop 157 Staffers in Restructuring

Mar 14 8:00pm BioSpace.com Featured News
  Life Sciences Jobs   ...
Read More

Those Mum Moments When You Lose It

Mar 14 5:50pm Pregnancy Exercise
I like model Tess Holliday’s Instagram, she’s one of those mums who’s not afraid to show her vulnerable side on social media, which is a nice change from all those perfectly curated images of immaculately dressed and coifed children doing adorable things in blindingly clean, artfully decorated houses. This week she posted a selfie of […]...
Read More

Pregnancy Diaries: Monster Moods

Mar 14 5:17pm Pregnancy Exercise
With my first pregnancy I seemed to get an overload of the calm, Zen pregnancy hormones. Not much ruffled my feathers, which was lucky as just as I entered the second trimester we went through a major restructure at work, which resulted in the majority of my colleagues losing their jobs and months of change […]...
Read More

AbbVie Receives An Upgrade From Vetr

Mar 14 4:46pm Biotech
On Tuesday, the Vetr crowd upgraded their rating for AbbVie Inc (NYSE: ABBV), from 3 stars (Hold), issued four days ago, to 4.5 stars (Strong Buy). At the time of the upgrade, crowd sentiment for AbbVie was generally positive, with 63 percent of Vetr user ratings bullish. Share price in the biopharma company has been trending up since mid-February, gaining over 8.5 percent. In that span, AbbVie ...Full story available on Benzinga.com...
Read More

White House on Obamacare repeal: 'This is it,' passing another plan will be 'unbelievably difficult'

Mar 14 4:16pm Health Care
The White House has a message for Republicans who oppose Obamacare: This is the best chance you'll get.
Read More